The U.S. Food and Drug Administration has approved a supplemental premarket authorization for Life Technologies' Oncomine Dx Express Test, extending its role as a companion diagnostic to detect ERBB2 (HER2) activating mutations in non-small cell lung cancer patients under consideration for sevabertinib therapy. The decision tightens the regulatory link between molecular stratification and targeted therapeutic eligibility in lung cancer, reframing HER2 status within an established companion diagnostic framework. For molecular diagnostics teams, the action shifts HER2 mutation analysis from a conditionally ordered study to a treatment-guiding variable embedded within an already deployed test workflow.
A new stratification lane for HER2-mutant NSCLC
Oncomine Dx Express Test now functions as a regulatory-grade companion diagnostic for sevabertinib, identifying patients whose tumors harbor activating ERBB2/HER2 mutations — the subset for whom the targeted agent is indicated. The supplemental premarket authorization folds HER2 mutation detection into a molecular workflow already operational across reference and hospital laboratories, allowing HER2 status to be reported alongside other biomarkers rather than as an isolated reflex. For pathology groups already running the Oncomine platform, the expansion broadens clinical utility without introducing additional instrumentation; for laboratories new to the assay, the designation establishes a defined regulatory framework for analytical validation and adoption.
Operational implications for molecular laboratories
From a laboratory operations standpoint, the approval moves HER2 mutation testing further into the routine algorithmic workup for advanced non-squamous NSCLC, narrowing the historical distance between HER2 status as a research-grade readout and a treatment-guiding variable. The companion diagnostic designation obligates adherence to the assay's analytical validation parameters — sample handling, minimum tumor input, variant calling criteria — that laboratories will need to mirror in standard operating procedures and reporting templates. Combined-panel ordering is likely to displace sequential single-gene testing, with downstream consequences for pre-analytic specimen stewardship, particularly in small biopsies where tissue input is constrained and triage decisions cascade into reportable gene lists.
What to watch next
The expansion situates sevabertinib alongside emerging HER2-directed regimens whose clinical deployment depends on validated molecular detection. Three trajectories warrant monitoring as uptake data mature: how sevabertinib availability translates into HER2 testing demand at referral hubs, whether subsequent HER2-directed agents secure companion diagnostic ties through Oncomine or competing platforms, and how broader practice codifies HER2 testing within the standard NSCLC molecular workup. The direction of the next regulatory cycle will determine whether HER2 mutation analysis becomes a routinely reflexed variable or remains a clinically contextualized, conditionally ordered study.